Selective haematological cancer eradication with preserved haematopoiesis
Simon Garaudé,Romina Marone,Rosalba Lepore,Anna Devaux,Astrid Beerlage,Denis Seyres,Alessandro Dell' Aglio,Darius Juskevicius,Jessica Zuin,Thomas Burgold,Sisi Wang,Varun Katta,Garret Manquen,Yichao Li,Clément Larrue,Anna Camus,Izabela Durzynska,Lisa C. Wellinger,Ian Kirby,Patrick H. Van Berkel,Christian Kunz,Jérôme Tamburini,Francesco Bertoni,Corinne C. Widmer,Shengdar Q. Tsai,Federico Simonetta,Stefanie Urlinger,Lukas T. Jeker
DOI: https://doi.org/10.1038/s41586-024-07456-3
IF: 64.8
2024-05-23
Nature
Abstract:Haematopoietic stem cell (HSC) transplantation (HSCT) is the only curative treatment for a broad range of haematological malignancies, but the standard of care relies on untargeted chemotherapies and limited possibilities to treat malignant cells after HSCT without affecting the transplanted healthy cells 1 . Antigen-specific cell-depleting therapies hold the promise of much more targeted elimination of diseased cells, as witnessed in the past decade by the revolution of clinical practice for B cell malignancies 2 . However, target selection is complex and limited to antigens expressed on subsets of haematopoietic cells, resulting in a fragmented therapy landscape with high development costs 2,3,4,5 . Here we demonstrate that an antibody–drug conjugate (ADC) targeting the pan-haematopoietic marker CD45 enables the antigen-specific depletion of the entire haematopoietic system, including HSCs. Pairing this ADC with the transplantation of human HSCs engineered to be shielded from the CD45-targeting ADC enables the selective eradication of leukaemic cells with preserved haematopoiesis. The combination of CD45-targeting ADCs and engineered HSCs creates an almost universal strategy to replace a diseased haematopoietic system, irrespective of disease aetiology or originating cell type. We propose that this approach could have broad implications beyond haematological malignancies.
multidisciplinary sciences